Pfizer 2015 Annual Report Download - page 70

Download and view the complete annual report

Please find page 70 of the 2015 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 134

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134

Consolidated Statements of Equity
Pfizer Inc. and Subsidiary Companies
2015 Financial Report
69
PFIZER INC. SHAREHOLDERS
Preferred Stock Common Stock Treasury Stock
(MILLIONS, EXCEPT PREFERRED SHARES) Shares
Stated
Value Shares
Par
Value
Add’l
Paid-In
Capital Shares Cost
Retained
Earnings
Accum.
Other
Comp.
Loss
Share -
holders’
Equity
Non-
controlling
Interests
Tota l
Equity
Balance, January 1, 2013 967 $ 39 8,956 $ 448 $ 72,608 (1,680) $(40,122) $ 54,240 $ (5,953) $ 81,260 $ 418 $ 81,678
Net income 22,003 22,003 69 22,072
Other comprehensive income/(loss), net of tax 2,655 2,655 (62) 2,593
Cash dividends declared:
Common stock (6,509) (6,509) (6,509)
Preferred stock (2) (2) (2)
Noncontrolling interests (121) (121)
Share-based payment transactions 95 5 2,390 (4) (99) 2,296 2,296
Purchases of common stock (563) (16,290) (16,290) (16,290)
Preferred stock conversions and redemptions (138) (6) (5) — — (11) (11)
Sale of 19.8% of subsidiary through an IPO(a) 2,297 27 2,324 155 2,479
Acquisition of common stock in exchange offer(a) (405) (11,408) (11,408) (11,408)
Deconsolidation of subsidiary sold(a) (145) (145)
Other — — (7) — (4) — (11) (1) (12)
Balance, December 31, 2013 829 33 9,051 453 77,283 (2,652) (67,923) 69,732 (3,271) 76,307 313 76,620
Net income 9,135 9,135 32 9,168
Other comprehensive income/(loss), net of tax (4,045) (4,045) 3 (4,042)
Cash dividends declared:
Common stock (6,690) (6,690) (6,690)
Preferred stock (2) (2) (2)
Noncontrolling interests (6) (6)
Share-based payment transactions 59 3 1,693 (2) (100) 1,597 1,597
Purchases of common stock (165) (5,000) (5,000) (5,000)
Preferred stock conversions and redemptions (112) (4) (4) — 1 (8) (8)
Other — — — (1) 5 — — — — 5 (22) (17)
Balance, December 31, 2014 717 29 9,110 455 78,977 (2,819) (73,021) 72,176 (7,316) 71,301 321 71,622
Net income 6,960 6,960 26 6,986
Other comprehensive income/(loss), net of tax (2,206) (2,206) (26) (2,232)
Cash dividends declared:
Common stock (7,141) (7,141) (7,141)
Preferred stock (2) (2) (2)
Noncontrolling interests — (16) (16)
Share-based payment transactions 67 3 2,015 (1) (72) 1,946 1,946
Purchases of common stock (182) (6,160) (6,160) (6,160)
Preferred stock conversions and redemptions (68) (3) (3) — 1 (5) (5)
Other — — — 27 — — — 27 (27) —
Balance, December 31, 2015 649 $ 26 9,178 $ 459 $ 81,016 (3,003) $(79,252) $ 71,993 $ (9,522) $ 64,720 $ 278 $ 64,998
(a) Relates to Zoetis (our former Animal Health subsidiary). See Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method
Investments and Cost-Method Investment: Divestitures.
Amounts may not add due to rounding.
See Notes to Consolidated Financial Statements, which are an integral part of these statements.